Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;115(4):559-65.
doi: 10.1007/s00702-007-0728-2. Epub 2007 Apr 26.

From poison to remedy: the chequered history of botulinum toxin

Affiliations
Review

From poison to remedy: the chequered history of botulinum toxin

F J Erbguth. J Neural Transm (Vienna). 2008.

Abstract

Botulinum toxin poisoning has afflicted mankind through the mists of time. However, the first incident of food-borne botulism was documented as late as the 18th century, when the consumption of meat and blood sausages gave rise to many deaths throughout the kingdom of Württemberg in South Western Germany. The district medical officer Justinus Kerner (1786--1862), who was also a well-known German poet, published the first accurate and complete descriptions of the symptoms of food-borne botulism between 1817 and 1822 and attributed the intoxication to a biological poison. Kerner also postulated that the toxin might be used for treatment purposes. In 1895, an outbreak of botulism in the small Belgian village of Ellezelles led to the discovery of the pathogen "Clostridium botulinum" by Emile Pierre van Ermengem. Modern botulinum toxin treatment was pioneered by Alan B. Scott and Edward J. Schantz in the early 1970s, when the type-A serotype was used in medicine to correct strabismus. Other preparations of the type-A toxin were developed and manufactured in the United Kingdom, Germany, and China, whereas a therapeutic type-B toxin was prepared in the United States. To date, the toxin has been used to treat a wide variety of conditions associated with muscular hyperactivity, glandular hypersecretions and pain.

PubMed Disclaimer

References

    1. Mov Disord. 2004 Mar;19 Suppl 8:S2-6 - PubMed
    1. BMJ. 1998 Jan 10;316(7125):151 - PubMed
    1. J Hist Neurosci. 2000 Aug;9(2):218-20 - PubMed
    1. Clin Med (Lond). 2001 Nov-Dec;1(6):502-4 - PubMed
    1. Neurology. 1999 Nov 10;53(8):1850-3 - PubMed

LinkOut - more resources